0OP Stock | | | EUR 5.76 0.00 0.00% |
CEO
Peter Miller is Chief Executive Officer, Director of OptiNose since 2010.
Age | 62 |
Tenure | 15 years |
Phone | 267 364 3500 |
Web | https://www.optinose.com |
OptiNose Management Efficiency
The company has return on total asset
(ROA) of
(0.312) % which means that it has lost $0.312 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(10.505) %, meaning that it generated substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities.
OptiNose has accumulated 126.42
M in total debt. OptiNose has a current ratio of 2.77, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist OptiNose until it has trouble settling it off, either with new capital or with free cash flow. So, OptiNose's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OptiNose sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OptiNose to invest in growth at high rates of return. When we think about OptiNose's use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 1 records | CEO Age |
| Anders Storm | SIVERS SEMICONDUCTORS AB | 50 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania. OPTINOSE INC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 204 people. OptiNose (0OP) is traded on Frankfurt Exchange in Germany and employs 189 people.
Management Performance
OptiNose Leadership Team
Elected by the shareholders, the OptiNose's board of directors comprises two types of representatives: OptiNose inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OptiNose. The board's role is to monitor OptiNose's management team and ensure that shareholders' interests are well served. OptiNose's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OptiNose's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandra Helton, Independent Director | |
| Tomas Heyman, Director | |
| Anthony Krick, VP Officer | |
| Ramy Mahmoud, President, Chief Operating Officer | |
| John Messina, Sr Affairs | |
| Catherine Owen, Director | |
| Jonathan Neely, VP Operations | |
| Joshua Tamaroff, Independent Director | |
| Joseph Scodari, Independent Chairman of the Board | |
| Keith Goldan, Chief Financial Officer | |
| Sriram Venkataraman, Independent Director | |
| Wilhelmus Groenhuysen, Independent Director | |
| Peter Miller, Chief Executive Officer, Director | |
| Michele MBA, VP CFO | |
| Robert ONeil, Independent Director | |
| Karen Brophy, Chief HR | |
| William Doyle, Independent Director | |
| Michael Esq, Chief Sec | |
| Victor Clavelli, Chief Commercial Officer | |
| Per MD, CoFounder AS | |
| Michael Marino, Chief Legal Officer and Corporate Secretary | |
| MPH MD, Pres COO | |
OptiNose Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OptiNose a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in OptiNose Stock
When determining whether OptiNose offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OptiNose's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Optinose Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Optinose Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in OptiNose Stock please use our
How to Invest in OptiNose guide.
You can also try the
Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.